WO1999048868A3 - Familles heterocycliques de composes destinees a la modulation de la tyrosine-kinase - Google Patents

Familles heterocycliques de composes destinees a la modulation de la tyrosine-kinase Download PDF

Info

Publication number
WO1999048868A3
WO1999048868A3 PCT/US1999/006468 US9906468W WO9948868A3 WO 1999048868 A3 WO1999048868 A3 WO 1999048868A3 US 9906468 W US9906468 W US 9906468W WO 9948868 A3 WO9948868 A3 WO 9948868A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
protein kinase
tyrosine protein
modulating
modulating tyrosine
Prior art date
Application number
PCT/US1999/006468
Other languages
English (en)
Other versions
WO1999048868A2 (fr
WO1999048868A9 (fr
Inventor
Annie Fong
Alison Hannah
David G Harris
Peter Hirth
Steven R Hubbard
Peter Langecker
Congxin Liang
Gerald Mcmahon
Moosa Mohammadi
Joseph Schlessinger
Laura K Shawver
Li Sun
Peng C Tang
Axel Ullrich
Original Assignee
Sugen Inc
Univ New York
Max Planck Inst Fur Biochemie
Annie Fong
Alison Hannah
David G Harris
Peter Hirth
Steven R Hubbard
Peter Langecker
Congxin Liang
Gerald Mcmahon
Moosa Mohammadi
Joseph Schlessinger
Laura K Shawver
Li Sun
Peng C Tang
Axel Ullrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc, Univ New York, Max Planck Inst Fur Biochemie, Annie Fong, Alison Hannah, David G Harris, Peter Hirth, Steven R Hubbard, Peter Langecker, Congxin Liang, Gerald Mcmahon, Moosa Mohammadi, Joseph Schlessinger, Laura K Shawver, Li Sun, Peng C Tang, Axel Ullrich filed Critical Sugen Inc
Priority to AU33635/99A priority Critical patent/AU3363599A/en
Priority to CA002325935A priority patent/CA2325935A1/fr
Priority to JP2000537851A priority patent/JP2002507598A/ja
Priority to EP99915018A priority patent/EP1066257A2/fr
Publication of WO1999048868A2 publication Critical patent/WO1999048868A2/fr
Publication of WO1999048868A3 publication Critical patent/WO1999048868A3/fr
Publication of WO1999048868A9 publication Critical patent/WO1999048868A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

L'invention concerne certains composés à base d'indolinone et de pyrazolylamide, leur méthode de synthèse, et des banques combinatoires constituées de ces composés. L'invention concerne également des méthodes utilisant ces composés qui permettent de moduler la fonction de protéines kinases, ainsi que des méthodes de traitement de maladies consistant à moduler la fonction des protéines kinases et les voies de transduction du signal associées.
PCT/US1999/006468 1998-03-26 1999-03-26 Familles heterocycliques de composes destinees a la modulation de la tyrosine-kinase WO1999048868A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU33635/99A AU3363599A (en) 1998-03-26 1999-03-26 Heterocyclic families of compounds for the modulation of tyrosine protein kinase
CA002325935A CA2325935A1 (fr) 1998-03-26 1999-03-26 Familles de composes heterocycliques pour la modulation de la tyrosine-proteine kinase
JP2000537851A JP2002507598A (ja) 1998-03-26 1999-03-26 チロシン蛋白質キナーゼを調節するためのヘテロ環式化合物のファミリー
EP99915018A EP1066257A2 (fr) 1998-03-26 1999-03-26 Familles heterocycliques de composes destinees a la modulation de la tyrosine-kinase

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US7971398P 1998-03-26 1998-03-26
US60/079,713 1998-03-26
US8042298P 1998-04-02 1998-04-02
US60/080,422 1998-04-02
US8179298P 1998-04-15 1998-04-15
US60/081,792 1998-04-15
US8205698P 1998-04-16 1998-04-16
US60/082,056 1998-04-16
US8939798P 1998-06-15 1998-06-15
US60/089,397 1998-06-15
US8952198P 1998-06-16 1998-06-16
US60/089,521 1998-06-16
US9878398P 1998-09-01 1998-09-01
US60/098,783 1998-09-01

Publications (3)

Publication Number Publication Date
WO1999048868A2 WO1999048868A2 (fr) 1999-09-30
WO1999048868A3 true WO1999048868A3 (fr) 2000-02-24
WO1999048868A9 WO1999048868A9 (fr) 2000-04-20

Family

ID=27568389

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006468 WO1999048868A2 (fr) 1998-03-26 1999-03-26 Familles heterocycliques de composes destinees a la modulation de la tyrosine-kinase

Country Status (5)

Country Link
EP (1) EP1066257A2 (fr)
JP (1) JP2002507598A (fr)
AU (1) AU3363599A (fr)
CA (1) CA2325935A1 (fr)
WO (1) WO1999048868A2 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6395734B1 (en) 1998-05-29 2002-05-28 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
TR200101858T2 (tr) 1998-12-17 2001-12-21 F.Hoffmann-La Roche Ag JNK protein kinaz inhibitörleri olarak 4-ariloksindoller
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
CA2354402A1 (fr) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles comme inhibiteurs de proteine kinase
CN1138773C (zh) 1998-12-17 2004-02-18 霍夫曼-拉罗奇有限公司 4-链烯基(和炔基)氧吲哚作为细胞周期蛋白-依赖性激酶尤其是cdk2的抑制剂
AU3208200A (en) 1999-01-13 2000-08-01 Research Foundation Of The State University Of New York, The A novel method for designing protein kinase inhibitors
ES2367007T3 (es) * 1999-11-24 2011-10-27 Sugen, Inc. Derivados de indolinona ionizables y su uso como ligandos de ptk.
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
AU784266B2 (en) * 1999-12-22 2006-03-02 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine kinase
JP2003535038A (ja) * 1999-12-30 2003-11-25 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節および癌化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
US20020028828A1 (en) 2000-05-02 2002-03-07 Chung-Chen Wei (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
JP2004529110A (ja) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ 脈管損傷活性を有するインドール誘導体
KR20040000507A (ko) * 2001-05-24 2004-01-03 야마노우치세이야쿠 가부시키가이샤 3-퀴놀린-2(1ｈ)-일리덴인돌린-2-온 유도체
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US20030119839A1 (en) * 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
WO2003070725A2 (fr) 2002-02-15 2003-08-28 Pharmacia & Upjohn Company Procede de preparation de derives de l'indolinone
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
BR0316229A (pt) 2002-11-13 2005-10-04 Chiron Corp Métodos de tratamento de câncer e métodos relacionados
AU2003284572A1 (en) * 2002-11-22 2004-06-18 Yamanouchi Pharmaceutical Co., Ltd. 2-oxoindoline derivatives
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
BRPI0507891A (pt) 2004-02-20 2007-07-24 Chiron Corp modulação dos processos inflamatório e metastático
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
SG154451A1 (en) 2005-05-23 2009-08-28 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1- yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
EP1978961B1 (fr) 2006-01-06 2016-03-16 Sunovion Pharmaceuticals Inc. Inhibiteurs de recaptage de monoamine a base de tetralone
EP1976513B1 (fr) 2006-01-06 2016-08-24 Sunovion Pharmaceuticals Inc. Cycloalkylamines inhibiteurs du recaptage des monoamines
DK2816024T3 (en) 2006-03-31 2017-10-30 Sunovion Pharmaceuticals Inc CHIRALE AMINER
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
EP1918277B1 (fr) * 2006-11-01 2015-06-10 Industrial Technology Research Institute Composés d'azulène
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
AU2008206039A1 (en) 2007-01-18 2008-07-24 Sepracor Inc. Inhibitors of D-amino acid oxidase
WO2008138184A1 (fr) * 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
MX2009012685A (es) 2007-05-31 2009-12-14 Sepracor Inc Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina.
AR068063A1 (es) 2007-08-27 2009-11-04 Basf Plant Science Gmbh Co mpuestos de pirazol para controlar plagas de invertebrados
JP2011505341A (ja) * 2007-11-21 2011-02-24 デコード ジェネティクス イーエイチエフ 炎症性、心血管およびｃｎｓ障害を治療するビアリールｐｄｅ４抑制剤
CN102223798A (zh) 2008-09-24 2011-10-19 巴斯夫欧洲公司 用于防治无脊椎动物害虫的吡唑化合物
CN102224149B (zh) 2008-09-24 2014-09-10 巴斯夫欧洲公司 防治无脊椎动物害虫的吡唑化合物
US8710056B2 (en) 2009-07-06 2014-04-29 Basf Se Pyridazine compounds for controlling invertebrate pests
EP2451804B1 (fr) 2009-07-06 2014-04-30 Basf Se Composés pyridazine destinés à la lutte contre les nuisibles invertébrés
CN102469785A (zh) 2009-07-24 2012-05-23 巴斯夫欧洲公司 防治无脊椎动物害虫的吡啶衍生物
US8569331B2 (en) 2010-11-01 2013-10-29 Arqule, Inc. Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013055A2 (fr) * 1990-02-28 1991-09-05 Farmitalia Carlo Erba S.R.L. Nouveaux derives d'aryl- et heteroarylethenylene, et leur procede de preparation
WO1992007830A2 (fr) * 1990-10-29 1992-05-14 Pfizer Inc. Antagonistes de peptide aux oxindoles
WO1992020642A1 (fr) * 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Composes aryle et heteroaryle bis monocycliques et/ou bicycliques qui inhibent la tyrosine kinase d'un recepteur du egf et/ou du pdgf
WO1994014808A1 (fr) * 1992-12-23 1994-07-07 Farmitalia Carlo Erba Srl Derives vinylene-azaindoliques et leur procede de preparation
WO1995024190A2 (fr) * 1994-03-07 1995-09-14 Sugen, Inc. Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant
WO1996000226A1 (fr) * 1994-06-24 1996-01-04 Pharmacia S.P.A. Composes azaindolylidene substitues et leur procede de preparation
WO1996016964A1 (fr) * 1994-11-28 1996-06-06 Pharmacia & Upjohn S.P.A Composes 3-arylidene-7-azaoxindoles substitues et leur procede de preparation
WO1996040116A1 (fr) * 1995-06-07 1996-12-19 Sugen, Inc. Composes d'indolinone pour le traitement de maladies
WO1998007695A1 (fr) * 1996-08-23 1998-02-26 Sugen, Inc. Banques combinatoires d'indolinone, produits et procedes associes pour traiter des maladies
WO1998045708A1 (fr) * 1997-04-08 1998-10-15 Sugen, Inc. Etude et traitement des maladies liees a des fonctions cellulaires specifiques de proteines tyrosines kinases receptrices
WO1998050356A1 (fr) * 1997-05-07 1998-11-12 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
WO1998056376A1 (fr) * 1997-06-13 1998-12-17 Sugen, Inc. Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013055A2 (fr) * 1990-02-28 1991-09-05 Farmitalia Carlo Erba S.R.L. Nouveaux derives d'aryl- et heteroarylethenylene, et leur procede de preparation
WO1992007830A2 (fr) * 1990-10-29 1992-05-14 Pfizer Inc. Antagonistes de peptide aux oxindoles
WO1992020642A1 (fr) * 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Composes aryle et heteroaryle bis monocycliques et/ou bicycliques qui inhibent la tyrosine kinase d'un recepteur du egf et/ou du pdgf
WO1994014808A1 (fr) * 1992-12-23 1994-07-07 Farmitalia Carlo Erba Srl Derives vinylene-azaindoliques et leur procede de preparation
WO1995024190A2 (fr) * 1994-03-07 1995-09-14 Sugen, Inc. Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant
WO1996000226A1 (fr) * 1994-06-24 1996-01-04 Pharmacia S.P.A. Composes azaindolylidene substitues et leur procede de preparation
WO1996016964A1 (fr) * 1994-11-28 1996-06-06 Pharmacia & Upjohn S.P.A Composes 3-arylidene-7-azaoxindoles substitues et leur procede de preparation
WO1996040116A1 (fr) * 1995-06-07 1996-12-19 Sugen, Inc. Composes d'indolinone pour le traitement de maladies
WO1998007695A1 (fr) * 1996-08-23 1998-02-26 Sugen, Inc. Banques combinatoires d'indolinone, produits et procedes associes pour traiter des maladies
WO1998045708A1 (fr) * 1997-04-08 1998-10-15 Sugen, Inc. Etude et traitement des maladies liees a des fonctions cellulaires specifiques de proteines tyrosines kinases receptrices
WO1998050356A1 (fr) * 1997-05-07 1998-11-12 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
WO1998056376A1 (fr) * 1997-06-13 1998-12-17 Sugen, Inc. Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GAZIT,A. ET AL.: "Tyrphostins. 2. Heterocyclic and alpha-Substituted Benzylidenmalonitirle Tyrphostins as Poitent Inhibitors of EGRF Receptor and ErbB2/neu Tyrosine Kinases", J.MED.CHEM., vol. 34, no. 6, June 1991 (1991-06-01), WASHINGTON, pages 1896 - 1907, XP000472938 *
LEVITZKI A ET AL: "TYROSINE KINASE INHIBITION: AN APPROACH TO DRUG DEVELOPMENT", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 267, March 1995 (1995-03-01), pages 1782-1788, XP002048355, ISSN: 0036-8075 *
MOHAMMADI M ET AL: "STRUCTURES OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR IN COMPLEX WITH INHIBITORS", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 276, no. 5314, pages 955-960, XP002065235, ISSN: 0036-8075 *
SPADA A P ET AL: "SMALL MOLECULE INHIBITORS OF TYROSINE KINASE ACTIVITY", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 5, no. 8, 1 January 1995 (1995-01-01), pages 805 - 817, XP000567587, ISSN: 1354-3776 *
SUN,LO. ET AL.: "Synthesis and Biological Evaluation of 3-Substituted Indolin-2-ones : A novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particualr Receptor Tyrosine Kinases", J.MED.CHEM., vol. 41, no. 14, 2 July 1998 (1998-07-02), WASHINGTON, pages 2588 - 2603, XP002122185 *
TRAXLER,P.M.: "Protein tyrosine kinase inhibitors in cancer treatment", EXP.OPIN.THER.PATENTS, vol. 7, no. 6, 1997, LONDON, pages 571 - 588, XP002122590 *

Also Published As

Publication number Publication date
WO1999048868A2 (fr) 1999-09-30
WO1999048868A9 (fr) 2000-04-20
AU3363599A (en) 1999-10-18
JP2002507598A (ja) 2002-03-12
CA2325935A1 (fr) 1999-09-30
EP1066257A2 (fr) 2001-01-10

Similar Documents

Publication Publication Date Title
WO1999048868A3 (fr) Familles heterocycliques de composes destinees a la modulation de la tyrosine-kinase
WO2001064681A3 (fr) Composes de 3-(pyrolyllactone)-2-indolinone comme inhibiteurs des kinases
EP1247803A3 (fr) Composés d'indolinone et leur utilisation comme modulateurs de la protéine kinase
EP1007042A4 (fr) Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine
ATE322491T1 (de) Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
DE69718472D1 (de) Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
NO20052497D0 (no) Fremgangsmater for selektiv inhibering av Janus tyrosinkinase 3 (JAK3).
GR20010300010T1 (en) Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
CY2014034I1 (el) Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
NO960079D0 (no) Oligonukleotid modulasjon av proteinkinase C
EP0831831A4 (fr) Composes de quinazoline aryle et heteroaryle avec proteine-tyrosine-kinase ayant des capacites d'inhibition selective des proprietes d'autophosphorylation de her-2
NO990124D0 (no) Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
ES2153337T1 (es) Inhibidores de raf-quinasa.
DE69627179T2 (de) Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren
NO974453D0 (no) Proteinkinase C-hemmere
ZA988797B (en) Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds.
WO2002048336A3 (fr) Peptides courts provenant de la 'region a' des proteines kinases modulant de maniere selective l'activite des proteines kinases
WO1999043830A3 (fr) Polypeptides d'heparanase des plaquettes humaines, molecules polynucleotidiques les codant et procedes d'identification de composes modifiant l'activite de l'heparanase
WO2005040073A3 (fr) Synthese en phase solide de 3-aryl-2-carboxamido-indolyl
WO2002022579A3 (fr) Heterocycles sulfonamides antipsychotiques et leurs methodes d'utilisation
NO975791D0 (no) Fremgangsmåte for fremstilling av spraybare, kationiske biopolymerer
WO1996040113A3 (fr) Inhibiteurs de la phosphatase
WO1997008190A3 (fr) Composes
WO2002092765A3 (fr) Nouveaux inhibiteurs de la telomerase et utilisations correspondantes
WO1999031128A3 (fr) Proteines du type facteur humain de necrose tumorale r2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 213-234, DESCRIPTION, REPLACED BY NEW PAGES 213-234; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2325935

Country of ref document: CA

Ref document number: 2325935

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 537851

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999915018

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999915018

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999915018

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)